ARCHIVES

Tafinlar Subgroup Data Shows Median OS of 20 Months

This article is from The Cancer Letter archive.

Vol. 37 No. 10 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

Compliance Grants Awarded, Contract Pending On Differences In Black/White Survival

November 19, 1982

FDA Approves 35 Medicines In Fiscal 2012, Eight in Cancer

December 28, 2012

In Brief: ASCO Congratulates Klausner; UCLA Names Gasson Head Of Jonsson Center

August 4, 1995

Group trials need prioritization, review, NCI official says.

July 25, 2003

National Dialogue On Cancer, The Cancer Act, And Activism.

February 4, 2000

ODAC Reviews Post-Marketing Studies for Eight Indications

March 21, 2003